HIV

NanoViricides, Inc. (stock symbol: NNVC.OB) is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. Utilizing nanoscale materials and processes licensed from TheraCour Pharma, Inc., we are developing anti-viral drugs against a wide range range of human and animal viruses.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases. The company developed Tyzeka/Sebivo through a co development agreement with Novartis Pharma AG for the treatment of patients with chronic hepatitis B in the United States and European Union for the treatment of patients with chronic hepatitis B.